본문 바로가기
R&D JW, leading global new drug development
Home

Research Pipeline

  • Discovery
  • Lead optimization
  • Pre-clinical
  • Phase Ⅰ
  • Phase II
  • Phase III
  • Registration
Cate
gory
Code name Development phase Being in adjustment
NCE URC-102
 
 
 
 
 
Gouty(Jointly developed with Japan's Chugai Company)
CWP291
 
 
 
 
Acute myelogenous leukemia(Polygenetic clinics)
CWP291
 
 
 
 
Multiple myeloma(Polygenetic clinics)
CWP291
 
 
 
 
cancer of the stomach
CWP291 Oral compound
 
 
Solid cancer
WNT activators
 
 
 
Histography
WNT inhibitors
 
 
Solid cancer, fibrosis
JWP1601
 
 
 
Atopy, Anti-inflammatory disease
NCE
 
 
 
Solid cancer

CWP232291

Innovative target therapy

  1. New-peptide epidephrodite compound
  2. Activision Mechanism : Increasing the Stress in the Cell to Suppress WNT-Business Caternity Signals

A full-time study

  1. No specific side effect
  2. In particular, it indicates superior efficacy in blood cancer.

    Acute myeloid leukaemia (AML) and multiple myeloma (multiple myeloma) :
    increase tumor growth and increase survival rates, change biological markers, and overcome drug resistance

Recurrent and re-related AML Patient Target Data1 Completed Phase 1 Completion

  1. There are no serious side effects, showing
    excellent durability
  2. Determine the appropriate dose amount
  3. Effect of independent administration (full / partial),
     and concentration of bio-marketing dependent on
     drug concentration

On-going clinical studies

  1. Acute myeloid leukemia (Phase Ib)- Detection and validation of the appropriate dose through a combination of standard treatments (Ara-C)
  2. Multiple myeloma (Phase Ia Ib)- exploring and verifying proper dosage dose by independent or combined administration
  3. cancer of the stomach (Phase/Ib)- Detection and effectiveness of proper dose management through combination of standard medications with standard treatment